![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 3 of 3. This is the beginning of the thread.
Posted by McPac on December 4, 2002, at 0:59:30
This product is called E.M. Power+
1: J Clin Psychiatry 2001 Dec;62(12):936-44 Related Articles, Links
Comment in:
J Clin Psychiatry. 2001 Dec;62(12):933-5.Effective mood stabilization with a chelated mineral supplement: an open-label trial in bipolar disorder.
Kaplan BJ, Simpson JS, Ferre RC, Gorman CP, McMullen DM, Crawford SG.
Faculty of Medicine, University of Calgary, Alberta Children's Hospital, Canada. kaplan@ucalgary.ca
BACKGROUND: To determine in open trials the therapeutic benefit of a nutritional supplement for bipolar disorder. METHOD: The sample consisted of 11 patients with DSM-IV-diagnosed bipolar disorder aged 19 to 46 years, who were taking a mean of 2.7 psychotropic medications each at study entry. Three additional patients dropped out prematurely. The intervention is a broad-based nutritional supplement of dietary nutrients, primarily chelated trace minerals and vitamins, administered in high doses. At study entry and periodically thereafter, patients were assessed with the Hamilton Rating Scale for Depression (HAM-D), the Brief Psychiatric Rating Scale (BPRS), and the Young Mania Rating Scale (YMRS). RESULTS: For those who completed the minimum 6-month open trial, symptom reduction ranged from 55% to 66% on the outcome measures; need for psychotropic medications decreased by more than 50%. Paired t tests revealed treatment benefit on all measures for patients completing the trial: HAM-D mean score at entry = 19.0, mean score at last visit = 5.4, t = 5.59, df = 9, p < 01; BPRS mean score at entry = 35.3, mean score at last visit = 7.4, t = 2.57, df = 9, p <.05; YMRS mean score at entry = 15.1, mean score at last visit = 6.0, t = 4.11, df = 9, p < .01. The effect size for the intervention was large (> .80) for each measure. The number of psychotropic medications decreased significantly to a mean +/- SD of 1.0+/-1.1 (t = 3.54, df = 10, p < .01). In some cases, the supplement replaced psychotropic medications and the patients remained well. The only reported side effect (i.e., nausea) was infrequent, minor, and transitory. CONCLUSION: Some cases of bipolar illness may be ameliorated by nutritional supplementation. A randomized, placebo-controlled trial in adults with bipolar I disorder is currently underway, as well as open trials in children.
Publication Types:
Clinical TrialPMID: 11780873 [PubMed - indexed for MEDLINE]
Posted by oracle on December 4, 2002, at 2:10:56
In reply to Positive BPClinical Trial for Nutritional Product , posted by McPac on December 4, 2002, at 0:59:30
> This product is called E.M. Power+
>
> Effective mood stabilization with a chelated mineral supplement: an open-label trial in bipolar disorder.Thsi means any product, or just a visit to the health store will do. No magic in E. M. here.
Till there are supporting studies the findings
carry much less merit. HRT was supported for years by studies, till a long enough studie proved we were killing people. Please just keep
the conxtext of one isolated study in mind.I wonder who paid for the study ?
Posted by Larry Hoover on December 4, 2002, at 8:02:35
In reply to Positive BPClinical Trial for Nutritional Product , posted by McPac on December 4, 2002, at 0:59:30
> This product is called E.M. Power+
>
> 1: J Clin Psychiatry 2001 Dec;62(12):936-44 Related Articles, Links
>
>
> Comment in:
> J Clin Psychiatry. 2001 Dec;62(12):933-5.
>
> Effective mood stabilization with a chelated mineral supplement: an open-label trial in bipolar disorder.
>
> Kaplan BJ, Simpson JS, Ferre RC, Gorman CP, McMullen DM, Crawford SG.
>
> Faculty of Medicine, University of Calgary, Alberta Children's Hospital, Canada. kaplan@ucalgary.ca
>
> BACKGROUND: To determine in open trials the therapeutic benefit of a nutritional supplement for bipolar disorder. METHOD: The sample consisted of 11 patients with DSM-IV-diagnosed bipolar disorder aged 19 to 46 years, who were taking a mean of 2.7 psychotropic medications each at study entry. Three additional patients dropped out prematurely.From a methodological perspective, open trials are at best suggestive, at the worst, useless. In an open trial, both the subject and the observers are aware of the treatment, providing all sorts of opportunities for conscious and subconscious bias. Also, failure to account for the 3 of 11 dropouts in statistical analyses artificially increases the outcome measures.
I review published work like this for a living. I'm not picking on Empower+.
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.